New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Researchers randomly assigned patients to receive oral semaglutide gradually titrated to the maximal, 14-mg dose or placebo ... “Delivery of this tablet is more complicated than usual ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...

Oral semaglutide 14 mg was associated with better cardiometabolic outcomes than active comparators, including empaglifozin and liraglutide, among patients with T2D. Oral semaglutide improves ...

The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide ... demonstrating a 14% reduction in risk of major ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...